knowledge -WSS

knowledge

author：explore 2025-10-02 22:24:56 - browse：5111

Blood corpuscles in clot — Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Using force crossed my mind when examining a defiant young patient

Wikipedia

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

Neuroscience renaissance leads to new crop of psychiatric drugs

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

With trial win, GSK could get blood cancer drug back on market

Let's speed up science by embracing open access publishing

explore

knowledge

explore

New air purifier tech could be key to improving indoor air quality

Change Healthcare can notify patients about the breach, HHS says

Medicare details structure of new drug price negotiation program

HIV drugs protect against transmission, even in unprotected sex

23andMe had bad news about my health. I wish a person had delivered it

Cholera vaccine supplies dangerously low, outbreaks surging

Alkermes shareholders re

Ionis drug prevents swelling attacks due to hereditary angioedema

BioMarin wins approval for gene therapy to treat hemophilia A

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

knowledge

5 ways to address the shortage of health care workers

Children’s Hospital revives plan for pedestrian bridge

Using force crossed my mind when examining a defiant young patient

ASCO: Palliative care found as helpful given virtually as in person

Medicare isn't yet testing food as medicine

Color Health wants to make cancer screenings convenient

leisure time

focus

Wikipedia

hotspot